Literature DB >> 9089744

Serum erythropoietin levels in patients with beta thalassemia major and intermedia.

G Nişli1, K Kavakli, Y Aydinok, S Oztop, N Cetingül.   

Abstract

Serum erythropoietin (EPO) levels were determined by radioimmunoassay in 37 beta-thalassemia patients, the phenotype being thalassemia major (TM) in 30 and thalassemia intermedia (TI) in 7. The control group consisted of 37 healthy children. The mean serum EPO levels were significantly higher in patients with both TM (215.1 +/- 144.5) and TI (53.8 +/- 40.2) compared with the control group (9.3 +/- 4.6). Although the mean hemoglobin (Hb) concentrations in the patients with TM and TI were similar (8.6 +/- 0.9 and 8.7 +/- 1.1, respectively), the mean serum EPO level was significantly higher in TM patients than the patients with TI (P < .01). This finding may indicate that some other factors contributing to the metabolic adaptation to low oxygen concentration or improvement of the tissue oxygenation are as effective as the Hb concentration in EPO production. It is also suggestive of the fact that some amount of tissue hypoxia cannot be prevented in spite of polytransfusion regimens in TM patients. Serum EPO levels of TM patients were not found to be age related or correlated with the mean pretransfusional Hb levels. In the TM patients, the serum EPO concentration was not consistently correlated with clinical signs of erythropoietic activity. This may be indicative of personal differences with respect to the sensitivities of erythroid precursors to the increasing EPO levels in TM patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9089744     DOI: 10.3109/08880019709030902

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  3 in total

1.  Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.

Authors:  Gian Luca Forni; Marina Podestà; Marco Musso; Giovanna Piaggio; Khaled M Musallam; Manuela Balocco; Sarah Pozzi; Alessandra Rosa; Francesco Frassoni
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

2.  Nephrectomy Does not Exacerbate Cancellous Bone loss in Thalassemic Mice.

Authors:  Sutada Lotinun; Korakot Atjanasuppat; Jutatip Limsuvech; Asada Leelahavanichkul; Saovaros Svasti; Nateetip Krishnamra
Journal:  Sci Rep       Date:  2020-05-08       Impact factor: 4.379

3.  The relation between mitogen activated protein kinase (MAPK) pathway and different genes expression in patients with beta Thalassemia.

Authors:  Yasser AbdElsattar Elghobashy; Mohamed Fa Assar; Asmaa A Mahmoud; Abdel Monem A Eltorgoman; Saher Elmasry
Journal:  Biochem Biophys Rep       Date:  2020-11-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.